Video

Dr. Pinato on Biomarker Challenges in HCC

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, Department of Surgery and Cancer, Imperial College London, discusses the lack of biomarkers in hepatocellular carcinoma (HCC).

Since the FDA approval of sorafenib (Nexavar) in 2007 for the treatment of patients with unresectable HCC, there had not been a novel therapy introduced to the treatment paradigm, says Pinato. As such, there was little clinical reason to biopsy patients as most of them received the same therapy.

Additionally, there are multiple subtypes of HCC, says Pinato. However, unlike ALK-positive non­—small cell lung cancer, for example, these subtypes are largely descriptive and lack actionable biomarkers that drive HCC progression.

Lastly, most institutions have abandoned performing routine biopsies for patients with HCC based on radiologic criteria, explains Pinato. Patients were not biopsied because there were limited therapy options, which led to a lack of molecular knowledge in HCC, which ultimately led to a lack of biomarker development, concludes Pinato.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD